1-Amino-guanosin | 19039-33-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 1-Amino-guanosin
• 英文别名: 1-Aminoguanosine；1,2-diamino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-one
• CAS: 19039-33-9
• 化学式: C₁₀H₁₄N₆O₅
• 分子量: 298.258
• InChiKey: PJBTXTKAGXQCNH-UUOKFMHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  172
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-Amino-guanosin 在 水 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 101.0h， 生成 1-amino-8-hydroxyguanosine
  参考文献：
  名称：

  Electrophilic amination of guanine derivatives. Mechanism for formation of 8-aminoguanine derivatives

  摘要：

  DOI：

  10.1016/s0040-4020(01)81962-1
• 作为产物：
  描述：

  鸟苷 在 hydroxylamine-O-sulfonic acid 作用下， 以 sodium hydroxide 为溶剂， 反应 24.0h， 以74%的产率得到1-Amino-guanosin
  参考文献：
  名称：

  Schlimme, Eckhard, Liebigs Annalen der Chemie, 1981, # 10, p. 1903 - 1906

  摘要：

  DOI：

文献信息

• TLR7 AGONISTS
  申请人：Primmune Therapeutics, Inc.

  公开号：US20210155652A1

  公开（公告）日：2021-05-27

  The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

  本发明涉及根据式I的TLR7激动剂及其在治疗癌症和传染病等疾病中的应用。
• [EN] COMPOSITIONS AND METHODS RELATED TO TETHERED KETHOXAL DERIVATIVES<br/>[FR] COMPOSITIONS ET PROCÉDÉS SE RAPPORTANT À DES DÉRIVÉS DE CÉTHOXAL ATTACHÉS
  申请人：UNIV CHICAGO

  公开号：WO2020237262A1

  公开（公告）日：2020-11-26

  Embodiments are directed to therapeutic, diagnostic, or functional complexes comprising a kethoxal derivative.

  具体实施方向是治疗、诊断或功能复合物，其中包括一个kethoxal衍生物。
• Methods for treatment using small molecule potassium-sparing diuretics and natriuretics
  申请人：University of Pittsburgh-Of the Commonwealth System of Higher Education

  公开号：US10729711B2

  公开（公告）日：2020-08-04

  Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substituted guanine and/or 8-substituted guanosine compounds are included in a beverage composition, which can be a fermented beverage, such as wine. Further, purine nucleoside phosphorylase (PNPase) inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can be used in methods of treating or reducing the risk of pulmonary hypertension (PH), such as PH associated with HIV or sickle cell disease (SCD). PNPase inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can also be used in methods of treating SCD or reducing sickling of red blood cells (RBCs).

  在此，8-取代鸟嘌呤和/或 8-取代鸟苷化合物可用于治疗高血压（如全身性或肺性高血压）、中风、糖尿病和/或需要利尿剂的患者。此外，8-取代鸟嘌呤和/或 8-取代鸟苷化合物还包含在饮料组合物中，饮料组合物可以是发酵饮料，如葡萄酒。此外，嘌呤核苷磷酸化酶（PNPase）抑制剂（如 8-取代鸟嘌呤和/或 8-取代鸟苷）和/或 PNPase 嘌呤核苷底物（如鸟苷和/或肌苷）可用于治疗或降低肺动脉高压（PH）风险的方法中，如与 HIV 或镰状细胞病（SCD）相关的 PH。PNP酶抑制剂（如8-取代鸟嘌呤和/或8-取代鸟苷）和/或PNP酶嘌呤核苷底物（如鸟苷和/或肌苷）也可用于治疗SCD或减少红细胞（RBC）镰状细胞病的方法中。
• Combinatorial derivatives of RNA oligonucleotides
  申请人：Farber Boris

  公开号：US11053608B2

  公开（公告）日：2021-07-06

  Field of application: This invention relates to the chemistry of nucleotides and allows to synthesize new combinatorial libraries of supramolecular oligonucleotides for use in medical fields, cosmetology and pharmaceutical industry. This invention also can be applied for the creation of means used in the body rejuvenation, treating human diseases such as cancer, trophic ulcers, creating new herbicides and pesticides. The essence of the invention Combinatorial derivatives of RNA oligonucleotides, wherein for their production, covalent modification of the initial RNA oligonucleotides is carried out by simultaneous combinatorial carboxylation and formylation of the exocyclic amino groups of adenine, guanine, cytosine and the ribose alcohol residue in the reaction with the maximum number of different synthesis derivatives, and as a result of synthesis, a combinatorial mixture of derivatives of each oligonucleotide is formed and then use the resulting combinatorial mixture as a whole without fragmentation to create biologically active compositions.

  应用领域：本发明涉及核苷酸化学，可以合成新的超分子寡核苷酸组合库，用于医疗、美容和制药领域。本发明还可用于创造人体年轻化的手段，治疗癌症、营养性溃疡等人类疾病，创造新的除草剂和杀虫剂。 本发明的实质是 RNA 寡核苷酸的组合衍生物，在生产过程中，通过同时对腺嘌呤、鸟嘌呤、胞嘧啶和核糖的外环氨基进行组合羧化和甲酰化，对初始 RNA 寡核苷酸进行共价修饰、胞嘧啶和核糖醇残基的外环氨基进行最大数量的合成衍生物反应，合成的结果是形成每种寡核苷酸衍生物的组合混合物，然后将得到的组合混合物作为一个整体使用，而不产生碎片，从而产生具有生物活性的组合物。
• Substituted purines as TLR7 agonists
  申请人：Primmune Therapeutics, Inc.

  公开号：US11059824B2

  公开（公告）日：2021-07-13

  The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

  本发明涉及根据式 I 的 TLR7 激动剂及其在治疗癌症和传染病等疾病中的用途。